| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| G J Remington, D Addington, E J Collins, B D Jones, P Lalonde, D J MacCrimmon, G W MacEwa. Clozapine: current status and role in the pharmacotherapy of schizophrenia. Canadian journal of psychiatry. Revue canadienne de psychiatrie. vol 41. issue 3. 1996-10-31. PMID:8722645. |
clozapine: current status and role in the pharmacotherapy of schizophrenia. |
1996-10-31 |
2023-08-12 |
Not clear |
| G J Remington, D Addington, E J Collins, B D Jones, P Lalonde, D J MacCrimmon, G W MacEwa. Clozapine: current status and role in the pharmacotherapy of schizophrenia. Canadian journal of psychiatry. Revue canadienne de psychiatrie. vol 41. issue 3. 1996-10-31. PMID:8722645. |
this study evaluates clozapine and its present role in the pharmacotherapy of schizophrenia. |
1996-10-31 |
2023-08-12 |
Not clear |
| J Grace, S B Bellus, M L Raulin, M I Herz, B L Priest, V Brenner, K Donnelly, P Smith, S Gun. Long-term impact of clozapine and psychosocial treatment on psychiatric symptoms and cognitive functioning. Psychiatric services (Washington, D.C.). vol 47. issue 1. 1996-10-28. PMID:8925344. |
the long-term effects of a combination of clozapine and psychosocial treatment were evaluated in a sample of treatment-refractory state hospital patients with schizophrenia. |
1996-10-28 |
2023-08-12 |
Not clear |
| A A Menditto, N C Beck, P Stuve, J A Fisher, M Stacy, M B Logue, L J Baldwi. Effectiveness of clozapine and a social learning program for severely disabled psychiatric inpatients. Psychiatric services (Washington, D.C.). vol 47. issue 1. 1996-10-28. PMID:8925345. |
this study examined the combined effectiveness of clozapine and a comprehensive inpatient psychosocial rehabilitation program on the clinical functioning and aggressive behaviors of patients with chronic schizophrenia. |
1996-10-28 |
2023-08-12 |
Not clear |
| R G Hammock, S R Schroeder, W R Levin. The effect of clozapine on self-injurious behavior. Journal of autism and developmental disorders. vol 25. issue 6. 1996-10-25. PMID:8720030. |
clozapine, a neuroleptic recently introduced in the united states, has proven effective in treatment of refractory cases of schizophrenia and is known to have an affinity for blocking d1 receptors. |
1996-10-25 |
2023-08-12 |
human |
| H C Liu, W H Chang, F C Wei, S K Lin, S K Lin, M W Jan. Monitoring of plasma clozapine levels and its metabolites in refractory schizophrenic patients. Therapeutic drug monitoring. vol 18. issue 2. 1996-10-21. PMID:8721285. |
plasma concentrations of clozapine and its metabolites desmethylclozapine and clozapine n-oxide were measured in 61 patients with refractory schizophrenia. |
1996-10-21 |
2023-08-12 |
Not clear |
| Y Talmon, N Guy, N Wittenber. [Clozapine for resistant schizophrenia and characteristics of those responding]. Harefuah. vol 129. issue 11. 1996-10-18. PMID:8846949. |
[clozapine for resistant schizophrenia and characteristics of those responding]. |
1996-10-18 |
2023-08-12 |
Not clear |
| Y Talmon, N Guy, N Wittenber. [Clozapine for resistant schizophrenia and characteristics of those responding]. Harefuah. vol 129. issue 11. 1996-10-18. PMID:8846949. |
clozapine (leponex) is an atypical antipsychotic drug which is effective in the treatment of resistant schizophrenia. |
1996-10-18 |
2023-08-12 |
Not clear |
| M S Sodhi, M J Arranz, D Curtis, D M Ball, P Sham, G W Roberts, J Price, D A Collier, R W Kerwi. Association between clozapine response and allelic variation in the 5-HT2C receptor gene. Neuroreport. vol 7. issue 1. 1996-10-17. PMID:8742444. |
we investigated this polymorphism in subjects with schizophrenia resistant to conventional neuroleptic drugs, and analysed our data for allelic association between the disease state or clinical response to the atypical antipsychotic drug, clozapine. |
1996-10-17 |
2023-08-12 |
human |
| M S Sodhi, M J Arranz, D Curtis, D M Ball, P Sham, G W Roberts, J Price, D A Collier, R W Kerwi. Association between clozapine response and allelic variation in the 5-HT2C receptor gene. Neuroreport. vol 7. issue 1. 1996-10-17. PMID:8742444. |
there was no association between schizophrenia and the 5-ht2cser allele, but our results indicate that the 5-ht2c receptor may contain the major site of action through which clozapine mediates its antipsychotic effects. |
1996-10-17 |
2023-08-12 |
human |
| M Avnon, J Rabinowit. Effectiveness of clozapine in hospitalised people with chronic neuroleptic-resistant schizophrenia. The British journal of psychiatry : the journal of mental science. vol 167. issue 6. 1996-10-17. PMID:8829743. |
effectiveness of clozapine in hospitalised people with chronic neuroleptic-resistant schizophrenia. |
1996-10-17 |
2023-08-12 |
Not clear |
| M Avnon, J Rabinowit. Effectiveness of clozapine in hospitalised people with chronic neuroleptic-resistant schizophrenia. The British journal of psychiatry : the journal of mental science. vol 167. issue 6. 1996-10-17. PMID:8829743. |
clozapine's effectiveness in reducing symptoms and facilitating discharge among patients with chronic schizophrenia who were resistant to neuroleptics was studied. |
1996-10-17 |
2023-08-12 |
Not clear |
| R W Buchana. Clozapine: efficacy and safety. Schizophrenia bulletin. vol 21. issue 4. 1996-09-26. PMID:8749886. |
clozapine (clozaril) represents the first major advance in the pharmacological treatment of schizophrenia since the introduction of antipsychotics into clinical practice in the 1950s. |
1996-09-26 |
2023-08-12 |
Not clear |
| H L Ewald, N P Mors, R Rosenber. [Dopamine D4-receptor variants, schizophrenia and clozapine therapy]. Ugeskrift for laeger. vol 158. issue 25. 1996-08-23. PMID:8693618. |
[dopamine d4-receptor variants, schizophrenia and clozapine therapy]. |
1996-08-23 |
2023-08-12 |
Not clear |
| H L Ewald, N P Mors, R Rosenber. [Dopamine D4-receptor variants, schizophrenia and clozapine therapy]. Ugeskrift for laeger. vol 158. issue 25. 1996-08-23. PMID:8693618. |
it is now possible to investigate if this variation influences individual differences in response to clozapine treatment or in the genetic susceptibility to schizophrenia. |
1996-08-23 |
2023-08-12 |
Not clear |
| H L Ewald, N P Mors, R Rosenber. [Dopamine D4-receptor variants, schizophrenia and clozapine therapy]. Ugeskrift for laeger. vol 158. issue 25. 1996-08-23. PMID:8693618. |
till now the examined variations in the drd4 gene do not seem to influence response to clozapine treatment or genetic susceptibility to schizophrenia. |
1996-08-23 |
2023-08-12 |
Not clear |
| S M Essock, W A Hargreaves, F A Dohm, J Goethe, L Carver, L Hipshma. Clozapine eligibility among state hospital patients. Schizophrenia bulletin. vol 22. issue 1. 1996-08-16. PMID:8685657. |
sixty percent of 803 patients with schizophrenia or schizoaffective disorder diagnoses met food and drug administration (fda)- approved criteria for clozapine use as judged by review of past medication trial records and by the responsible physicians. |
1996-08-16 |
2023-08-12 |
Not clear |
| b' R Lisulov, A Nedi\\xc4\\x8. [Maintenance therapy with low doses of clozapine in schizophrenia]. Medicinski pregled. vol 48. issue 1-2. 1996-07-31. PMID:8657050.' |
[maintenance therapy with low doses of clozapine in schizophrenia]. |
1996-07-31 |
2023-08-12 |
Not clear |
| W H Wilso. Time required for initial improvement during clozapine treatment of refractory schizophrenia. The American journal of psychiatry. vol 153. issue 7. 1996-07-29. PMID:8659622. |
time required for initial improvement during clozapine treatment of refractory schizophrenia. |
1996-07-29 |
2023-08-12 |
Not clear |
| P Buckley, J Bartell, K Donenwirth, S Lee, F Torigoe, S C Schul. Violence and schizophrenia: clozapine as a specific antiaggressive agent. The Bulletin of the American Academy of Psychiatry and the Law. vol 23. issue 4. 1996-07-16. PMID:8639988. |
violence and schizophrenia: clozapine as a specific antiaggressive agent. |
1996-07-16 |
2023-08-12 |
Not clear |